Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Dec 2024 value amounting to $39.6 million.

  • Maravai Lifesciences Holdings' Accumulated Expenses rose 23.75% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year increase of 23.75%. This contributed to the annual value of $39.6 million for FY2024, which is 34.30% down from last year.
  • Maravai Lifesciences Holdings' Accumulated Expenses amounted to $39.6 million in FY2024, which was down 34.30% from $60.2 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Accumulated Expenses ranged from a high of $60.2 million in FY2023 and a low of $34.6 million during FY2021.
  • For the 3-year period, Maravai Lifesciences Holdings' Accumulated Expenses averaged around $51.1 million, with its median value being $53.4 million (2022).
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Accumulated Expenses skyrocketed by 54.37% in 2022, and later slumped by 34.30% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' Accumulated Expenses (Yearly) stood at $38.5 million in 2020, then decreased by 10.30% to $34.6 million in 2021, then surged by 54.37% to $53.4 million in 2022, then rose by 12.86% to $60.2 million in 2023, then crashed by 34.30% to $39.6 million in 2024.